Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
SDX Energy PLC Announces Appointment of Joint Corporate Broker
-
Cantor Fitzgerald Reiterates Overweight Rating on Aravive Inc. (ARAV)
-
HMS Holdings (HMSY) PT Lowered to $33 at Cantor Fitzgerald
-
Pre-Open Stock Movers 02/21: (BXRX) (CRC) (DBX) Higher (TRUE) (BXC) (EYPT) Lower (more...)
-
After-Hours Stock Movers 02/20: (ZIXI) (EHTH) (DBX) Higher (EYPT) (TRUE) (FSLR) Lower (more...)
-
Orchid Island Capital Announces Fourth Quarter 2019 Results
-
Cantor Fitzgerald Starts Celldex Therapeutics (CLDX) at Overweight
-
Energy Fuels Announces Closing of Previously Announced US$16,611,000 Bought Deal Offering
-
Cantor Fitzgerald Reiterates Overweight Rating on Mesoblast Limited (MESO)
-
Cantor Fitzgerald Reiterates Overweight Rating on Heron Therapeutics (HRTX)
-
Reata Pharmaceuticals (RETA) PT Raised to $320 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Downgrades Tivity Health (TVTY) to Neutral
-
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
-
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
-
Stealth BioTherapeutics (MITO) PT Raised to $10 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Aridis Pharmaceuticals to Host Investor Day Showcasing APEX™ Technology Platform and Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
-
Freddie Mac Announces Pricing of $379 Million Multifamily Small Balance Loan Securitization
-
Canopy Growth (WEED:CN) (CGC) PT Raised to Cdn$32 at Cantor Fitzgerald
-
Endava PLC (ADR) (DAVA) PT Raised to $56 at Cantor Fitzgerald
-
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $12 at Cantor Fitzgerald
-
Agios Pharma (AGIO) PT Raised to $70 at Cantor Fitzgerald
-
Fidelity National Information Services (FIS) PT Raised to $175 at Cantor Fitzgerald
-
Energy Fuels Announces US$16.6 Million Common Share Bought Deal
-
Cantor Fitzgerald Starts Trulieve Cannabis Corp (TRUL:CN) (TCNNF) at Overweight
-
Pre-Open Stock Movers 02/13: (APT) (RDFN) (FBIO) Higher (XBIT) (AKRX) (NTAP) Lower (more...)
-
Global Payments (GPN) PT Raised to $225 at Cantor Fitzgerald
-
Moody's Corp (MCO) PT Raised to $266 at Cantor Fitzgerald
-
CVS Health (CVS) PT Raised to $90 at Cantor Fitzgerald
-
After-Hours Stock Movers 02/12: (RDFN) (FBIO) (AMAT) Higher; (BE) (NTAP) (CSCO) Lower (more...)
-
UPDATE: Cantor Fitzgerald Starts Fortress Biotech (FBIO) at Overweight
-
Teva Pharma (TEVA) PT Raised to $15 at Cantor Fitzgerald
-
Freddie Mac Prices $731 Million Multifamily K-Deal, K-F74
-
PolarityTE (PTE) Prices Offering of Common Stock and Warrants
-
PolarityTE Announces Pricing of Public Offering of Common Stock and Warrants
-
Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
-
Mereo BioPharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
-
Orchid Island Capital Announces February 2020 Monthly Dividend and January 31, 2020 RMBS Portfolio Characteristics
-
Computer Programs and Systems (CPSI) PT Raised to $32 at Cantor Fitzgerald Following 4Q
-
PolarityTE (PTE) to Offer Common Stock
-
PolarityTE Announces Public Offering of Common Stock and Warrants
-
Pre-Open Stock Movers 2/10: (VTVT) (EPC) (TSLA) Higher (ABUS) (BHVN) (LLY) Lower (more...)
-
NYC Department of Education and Partnership for New York City Launch City’s First Career Discovery Week, February 10-14
-
Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million
-
Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million
-
UPDATE: Cantor Fitzgerald Upgrades Adverum Biotechnologies (ADVM) to Overweight
-
Makor Capital Hires Talal Dehbi as New Managing Partner for Its Products Desk
-
Collegium Pharmaceutical (COLL) PT Raised to $30 at Cantor Fitzgerald
-
S&P Global (SPGI) PT Raised to $325 at Cantor Fitzgerald
-
Raptor Technology (RAPT) Prices 2.5M Common Stock Offering at $30/Share

